Posts

What Individual Investors Don't See Until It's Too Late: The Arithmetic of a Headline Deal

On 30 July 2026, Korea's Financial Supervisory Service published its comprehensive plan to overhaul pharmaceutical and biotech disclosure. The reform is unusually specific about a single number: the total value of a technology-transfer agreement. Under the new framework, a licensing deal can no longer be disclosed as one figure. Companies must break it into four lines — upfront payment, development milestones, approval and sales milestones, and royalties — and state the payment condition and character of each. The FSS was explicit about why: because only the total was published, milestones and royalties, which are payable solely on the satisfaction of conditions, were being read as amounts already secured at signing. The reform reaches further back than that. At the IPO stage, the assumptions behind a valuation must now be set out in four standardised categories: expected market size, probability of clinical success, approval and review risk, and development period and cost. Expe...

The Zombie Pattern: How Distressed Companies Drain Before They Fall

Two corporate decisions landed within days of each other in late July 2026, and between them they expose how badly the market reads reinvestment. On 27 July, Japan's Seven & i Holdings confirmed it had walked away from talks to take a stake in Żabka Group, the largest convenience store operator in Poland. Reporting put the contemplated stake at several tens of a percent and the transaction value in the hundreds of billions of yen. Seven & i's explanation was unusually plain: it could not reach agreement with the seller on terms it considered to be in the interest of its shareholders and other stakeholders. This was not a company without ambition. It is publicly targeting growth from roughly 87,000 stores to 100,000 by 2030, and its European footprint is currently thin — around 360 stores concentrated in the Nordics. Żabka would have been a Central European foothold with 10,000 franchised stores and 27.15bn zlotys ($7.16bn) of revenue in the twelve months to December 202...

Follow the Cash: When Raised Capital Doesn't Move

The Capital Efficiency Signal: When Invested Capital Turns Around

 On 24 July 2026, SK Inc. disclosed a tender offer for SK Signet, its EV fast-charger subsidiary listed on Korea's KONEX market. The terms are unremarkable on their face: ₩8,200 per common and convertible preferred share, more than a 20% premium to the one-month volume-weighted average price, for up to 10,072,587 shares — about ₩82.6bn if fully taken up. The offer runs 24 July to 24 August, settling 26 August. SK's voting stake rises from 66.71% to an expected 99.77%, with any stub acquired through a comprehensive share exchange. Delisting and full-subsidiary status are targeted for the fourth quarter; a sale of the unit, for the first quarter of 2027. SK's own framing is portfolio rebalancing: clear a non-core asset, free up investment capacity. The company also noted that a share exchange alone would have achieved 100% ownership, and that running a premium tender first was a shareholder-protection choice. Both statements are defensible. What makes this a capital efficie...

This Week's Risk Radar: What RaymondsIndex Is Watching

A clause that knew On 13 February 2026, Yuil Energy Tech (KOSDAQ: 340930), a battery-equipment maker, disclosed a control transfer. A financial investor group led by Kim Woo-gyeom, with five others, agreed to buy 19.1 million shares from the incumbent controlling shareholder at ₩785 apiece — ₩15.0 billion in total. The schedule was ordinary: a ₩1.1bn deposit on signing, then ₩2.2bn, ₩1.1bn and ₩1.1bn through 17 March, with 6.0 million shares moving as each tranche cleared. Clause 8 was not ordinary. It stated that if the company's external audit produced an adverse opinion or a disclaimer, the buyer's remaining obligations — a ₩6.6bn fourth instalment and a ₩2.9bn balance — would be waived, and so would the seller's obligation to deliver the remaining 13.1 million shares. On 31 March, the auditor issued a disclaimer: scope limitation plus going-concern uncertainty. Trading was suspended on 1 April. The company filed an...

Decoding RaymondsIndex: What "Validation" Actually Means for a Leading Risk Score

This week gave us a clean picture of how markets discover risk the slow way . Korea's exchanges classified 284 listings as a potential risk group — 74 on KOSPI and 210 on KOSDAQ — as the KOSDAQ index sat below 1,000 points for more than a month. Alongside it: 137 KOSDAQ names trading under ₩1,000, and a rule change that pulls full-capital-erosion companies into delisting review from the August half-year reports. Roughly 50 KOSDAQ names are already at delisting risk on the market-cap threshold alone. Read that list carefully and you notice something: every criterion on it is backward-looking. A share price under ₩1,000. A market cap beneath the line. Negative shareholder equity. These are outcomes — the last visible symptoms of decisions that were made quarters earlier. By the time a company qualifies for the "risk group," the capital efficiency has already decayed, the raised cash has already gone idle, the reinvestment has already been skipped. A lagging screen is hones...

When the Network Becomes Destiny: How This Summer's Convertible-Bond Rush Reveals the Retailization Pattern

In the first half of 2026, Korean investors exercised ₩3.24 trillion of equity-linked bonds through the Korea Securities Depository — up 21.7% from the prior half, across 3,166 separate exercises (+10.7%). Buried in that total is a sharper signal: exchangeable-bond (EB) conversions alone surged 95.7%, from ₩0.83 trillion to ₩1.62 trillion in six months. That single line drove most of the increase. Convertible bonds (CB), exchangeable bonds (EB), and warrant bonds (BW) are the everyday financing tools of lower-rated companies — disproportionately KOSDAQ small-caps. The instrument is elegant and quiet: if the stock disappoints, the holder collects interest; if the stock rises, the holder converts and captures the gain. The asymmetry is structural. The bondholder — often the issuer’s insiders or the funds that underwrote the paper — decides when to convert, armed with the best possible read of the company. The retail investor who bought the stock during its run-up decides nothing. They s...